242 related articles for article (PubMed ID: 7591267)
1. Bidirectional interactions between the estrogen receptor and the cerbB-2 signaling pathways: heregulin inhibits estrogenic effects in breast cancer cells.
Grunt TW; Saceda M; Martin MB; Lupu R; Dittrich E; Krupitza G; Harant H; Huber H; Dittrich C
Int J Cancer; 1995 Nov; 63(4):560-7. PubMed ID: 7591267
[TBL] [Abstract][Full Text] [Related]
2. Involvement of heregulin-beta2 in the acquisition of the hormone-independent phenotype of breast cancer cells.
Tang CK; Perez C; Grunt T; Waibel C; Cho C; Lupu R
Cancer Res; 1996 Jul; 56(14):3350-8. PubMed ID: 8764133
[TBL] [Abstract][Full Text] [Related]
3. Effect of estradiol on estrogen receptor-alpha gene expression and activity can be modulated by the ErbB2/PI 3-K/Akt pathway.
Stoica GE; Franke TF; Moroni M; Mueller S; Morgan E; Iann MC; Winder AD; Reiter R; Wellstein A; Martin MB; Stoica A
Oncogene; 2003 Sep; 22(39):7998-8011. PubMed ID: 12970748
[TBL] [Abstract][Full Text] [Related]
4. Expression of human estrogen receptor using an efficient adenoviral gene delivery system is able to restore hormone-dependent features to estrogen receptor-negative breast carcinoma cells.
Lazennec G; Katzenellenbogen BS
Mol Cell Endocrinol; 1999 Mar; 149(1-2):93-105. PubMed ID: 10375022
[TBL] [Abstract][Full Text] [Related]
5. 1alpha,25-Dihydroxyvitamin D3 down-regulates estrogen receptor abundance and suppresses estrogen actions in MCF-7 human breast cancer cells.
Swami S; Krishnan AV; Feldman D
Clin Cancer Res; 2000 Aug; 6(8):3371-9. PubMed ID: 10955825
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the characteristic of estrogenic action patterns of beta-HCH and heregulin beta1 in MCF-7 human breast cancer cells.
Hatakeyama M; Zou E; Matsumura F
J Biochem Mol Toxicol; 2002; 16(5):209-19. PubMed ID: 12439862
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of cell proliferation by 17beta-estradiol and heregulin beta1 in estrogen receptor negative human breast carcinoma cell lines.
Yoo JY; Lessor T; Hamburger AW
Breast Cancer Res Treat; 1998 Sep; 51(1):71-81. PubMed ID: 9877030
[TBL] [Abstract][Full Text] [Related]
8. Heregulin Drives Endocrine Resistance by Altering IL-8 Expression in ER-Positive Breast Cancer.
Papadimitropoulou A; Vellon L; Atlas E; Steen TV; Cuyàs E; Verdura S; Espinoza I; Menendez JA; Lupu R
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33086721
[TBL] [Abstract][Full Text] [Related]
9. Expression of c-erbB receptors, heregulin and oestrogen receptor in human breast cell lines.
deFazio A; Chiew YE; Sini RL; Janes PW; Sutherland RL
Int J Cancer; 2000 Aug; 87(4):487-98. PubMed ID: 10918187
[TBL] [Abstract][Full Text] [Related]
10. Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines.
Pink JJ; Jordan VC
Cancer Res; 1996 May; 56(10):2321-30. PubMed ID: 8625307
[TBL] [Abstract][Full Text] [Related]
11. TCDD elevates erbB2 expression and signaling in T47D cells by reversing serum potentiation of estrogen receptor activity, independent of estrogen levels and enhanced ER down-regulation.
Angus WG; Campaigne Larsen M; Jefcoate CR
Mol Cell Endocrinol; 2000 Dec; 170(1-2):1-13. PubMed ID: 11162886
[TBL] [Abstract][Full Text] [Related]
12. Targeted inhibition of tumor-cell growth by recombinant heregulin-toxin fusion proteins.
Jeschke M; Wels W; Dengler W; Imber R; Stöcklin E; Groner B
Int J Cancer; 1995 Mar; 60(5):730-9. PubMed ID: 7860149
[TBL] [Abstract][Full Text] [Related]
13. Antagonism of oestrogen action in human breast and endometrial cells in vitro: potential novel antitumour agents.
Nuttall ME; Pendrak I; Emery JG; Nadeau DP; Fisher PW; Nicholson TA; Zhu Y; Suva LJ; Kingsbury WD; Gowen M
Cancer Chemother Pharmacol; 2001 May; 47(5):437-43. PubMed ID: 11391860
[TBL] [Abstract][Full Text] [Related]
14. Novel estrogenic action of the pesticide residue beta-hexachlorocyclohexane in human breast cancer cells.
Steinmetz R; Young PC; Caperell-Grant A; Gize EA; Madhukar BV; Ben-Jonathan N; Bigsby RM
Cancer Res; 1996 Dec; 56(23):5403-9. PubMed ID: 8968093
[TBL] [Abstract][Full Text] [Related]
15. Mitogenic activity of neu differentiation factor/heregulin mimics that of epidermal growth factor and insulin-like growth factor-I in human mammary epithelial cells.
Ram TG; Kokeny KE; Dilts CA; Ethier SP
J Cell Physiol; 1995 Jun; 163(3):589-96. PubMed ID: 7775601
[TBL] [Abstract][Full Text] [Related]
16. Heregulin controls ERα and HER2 signaling in mammospheres of ERα-positive breast cancer cells and interferes with the efficacy of molecular targeted therapy.
Fukui F; Hayashi SI; Yamaguchi Y
J Steroid Biochem Mol Biol; 2020 Jul; 201():105698. PubMed ID: 32404282
[TBL] [Abstract][Full Text] [Related]
17. Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1.
Lykkesfeldt AE; Madsen MW; Briand P
Cancer Res; 1994 Mar; 54(6):1587-95. PubMed ID: 8137264
[TBL] [Abstract][Full Text] [Related]
18. Regulation of HRG-β1-induced proliferation, migration and invasion of MCF-7 cells by upregulation of GPR30 expression.
Ruan SQ; Wang SW; Wang ZH; Zhang SZ
Mol Med Rep; 2012 Jul; 6(1):131-8. PubMed ID: 22576740
[TBL] [Abstract][Full Text] [Related]
19. Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification.
Ram TG; Ethier SP
Cell Growth Differ; 1996 May; 7(5):551-61. PubMed ID: 8732665
[TBL] [Abstract][Full Text] [Related]
20. Interactions between progestins and heregulin (HRG) signaling pathways: HRG acts as mediator of progestins proliferative effects in mouse mammary adenocarcinomas.
Balañá ME; Lupu R; Labriola L; Charreau EH; Elizalde PV
Oncogene; 1999 Nov; 18(46):6370-9. PubMed ID: 10597237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
